ELV Rallies After Q3 Print as Defensive Options Bets Unwind

Elevance Health has printed its Q3 results and the market's pre-earnings defensiveness is visibly unwinding, with the stock up 3.5% on the week to $440.18 and options hedges rolling off.

The shift in options positioning is the clearest signal that the earnings anxiety has passed. Before Tuesday's print, the put/call ratio had touched 0.97, the 52-week high. It has since dropped back to 0.87, now sitting roughly 0.6 standard deviations below the 20-day average of 0.90. That is a meaningful reversal: the market was paying for downside protection ahead of the Q3 release and is now less inclined to do so. The previous note flagged that defensive posture as the dominant story. The data has moved in the opposite direction since then, and the setup looks measurably calmer. The lending market corroborates the lighter mood. Short interest has fallen 21% over the past month to just over 2% of the free float. Borrow availability is effectively uncapped, with over 130 million shares available to lend against the roughly 4.6 million currently borrowed. Cost to borrow at 0.44% is minimal, down 10% on the week despite a 48% rise over the prior month. There is no pressure building from bears in the lending pool.

The Street remains cautiously constructive, though not uniformly bullish. Within the past 14 days, Guggenheim raised its target to $460 while maintaining a Buy, and Barclays lifted to $469 on an Overweight. The mean analyst price target sits at $453, around 3% above the current price, suggesting limited near-term upside priced in by the consensus. Bulls point to the company's Medicare Advantage margin improvement, projected to exceed 150 basis points in 2026, and the strength of its Blue Cross Blue Shield positioning across 45 million medical members. Bears flag the Medicaid margin pressure and a lowered earnings outlook for 2026, with some estimates as low as $25.54 per share. Factor scores lean constructive on a 12-month forward earnings growth basis, ranking in the 89th percentile, while EPS momentum scores over both 30-day and 90-day windows are roughly in line with the broader universe at 48 and 44 respectively. The PE multiple has expanded about 0.9 turns over the past 30 days to 15.1x, reflecting the post-earnings re-rating. The short score has edged up to 34.3 from around 33.9 a week ago, a marginal move that does not change the picture materially.

One ownership detail worth noting is the CEO's position. Gail Boudreaux made two open-market purchases on July 17, totalling 2,725 shares at prices around $367 to $368, for a combined outlay of just over $1 million. That was shortly after July's 13% single-day decline following the Q2 release. The CFO, Mark Kaye, received a restricted share award on October 2 accompanied by a tax-withholding sale of 4,161 shares at $386, a routine compensation mechanic. Net insider activity over the past 90 days is a positive 3,725 shares, though the headline is dominated by the CEO's discretionary purchases at the July lows rather than any fresh conviction buying at current prices. Among large holders, Wellington added nearly a million shares as of its August filing, while Harris Associates added 313,000. BlackRock and State Street both added incrementally as of September 30.

The managed care peer group is also recovering this week. CNC added 2.8% on the week, MOH gained 4.9%, and CI rose 8.5%. UNH was the standout, up nearly 11% on the week. ELV's 3.5% move is solid in absolute terms but modest relative to several peers, suggesting some of the sector recovery is being driven by names that sold off more sharply earlier. The next earnings event for ELV is not scheduled until January 27, 2027, so the focus from here shifts to whether the sector-wide Medicaid reimbursement dynamic improves, what management has said about Q4 commercial trends, and whether analyst targets begin to cluster more tightly around the current price or diverge further as the Q3 detail is digested.